Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats.: Part II -: Tissue distribution

被引:67
作者
Bargoni, A
Cavalli, R
Zara, GP
Fundarò, A
Caputo, O
Gasco, MR
机构
[1] Univ Turin, Dipartimento Sci & Tecnol Farmaco, I-10125 Turin, Italy
[2] Univ Turin, Dipartimento Fisiopatol Clin, I-10125 Turin, Italy
[3] Univ Turin, Dipartimento Anat Farmacol & Med Legale, I-10125 Turin, Italy
关键词
duodenal administration; intravenous administration; tobramycin-loaded solid lipid nanoparticles; tobramycin tissue distribution; blood-brain barrier;
D O I
10.1006/phrs.2001.0813
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tobramycin-loaded solid lipid nanoparticles (SLN) were prepared and administered by duodenal and intravenous (i.v.) routes to rats and the tissue distributions were determined successively at fixed times (30 min, 4 h and 24 h) and compared to those of the tobramycin solution after i.v. administration. The tissue distribution between tobramycin-loaded SLN administered duodenally and i.v. was different.. A marked difference between tobramycin-loaded SLN administered duodenally and tobramycin solution administered i.v. was also evidenced. In particular, the amounts of tobramycin in the kidneys after tobramycin-loaded SLN administration either duodenally or i.v. were lower than after administration of i.v. solution. Tobramycin-loaded SLN were able to pass across the blood-brain barrier in rats to a greater extent after i.v. injection than after duodenal administration. (C) 2001 Academic Press.
引用
收藏
页码:497 / 502
页数:6
相关论文
共 38 条
[1]   Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles [J].
Alyautdin, RN ;
Petrov, VE ;
Langer, K ;
Berthold, A ;
Kharkevich, DA ;
Kreuter, J .
PHARMACEUTICAL RESEARCH, 1997, 14 (03) :325-328
[2]  
[Anonymous], USE ANTIBIOTICS
[3]   Intestinal transport of gentamicin with a novel, glycosteroid drug transport agent [J].
Axelrod, HR ;
Kim, JS ;
Longley, CB ;
Lipka, E ;
Amidon, GL ;
Kakarla, R ;
Hui, YW ;
Weber, SJ ;
Choe, S ;
Sofia, MJ .
PHARMACEUTICAL RESEARCH, 1998, 15 (12) :1876-1881
[4]   Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein [J].
Banerjee, SK ;
Jagannath, C ;
Hunter, RL ;
Dasgupta, A .
LIFE SCIENCES, 2000, 67 (16) :2011-2016
[5]   Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats [J].
Bargoni, A ;
Cavalli, R ;
Caputo, O ;
Fundarò, A ;
Gasco, MR ;
Zara, GP .
PHARMACEUTICAL RESEARCH, 1998, 15 (05) :745-750
[6]  
BARGONI A, 2000, P INT S CONTR REL BI, V27
[7]   In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against Gram-negative and Gram-positive bacteria [J].
Beaulac, C ;
Sachetelli, S ;
Lagace, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (01) :35-41
[8]   Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection [J].
Beaulac, C ;
ClementMajor, S ;
Hawari, J ;
Lagace, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :665-669
[9]  
BRIADLS DJ, 1978, ANTIMICROB AGENTS CH, V34, P269
[10]  
BROWN DA, J CHEM SOC, P1584